Adriamycin

(Doxorubicin)

ApprovedSmall molecule

Doxorubicin is a chemotherapy drug used to treat various types of cancer by damaging cancer cells and stopping them from growing and dividing. It's commonly used for breast cancer, lymphomas, and leukemias.[2] Adriamycin is currently approved and in use across 119 indications[4].[1]

Adriamycin is one of 1410 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Approved.

119

Indications

671

Total Trials

Active Trials

1,409

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

Peritoneum CancerApproved

Bacterial DiseaseActive, not recruiting

Urinary Bladder CarcinomaApproved

Non-Hodgkins LymphomaApproved

Uterine LeiomyosarcomaActive, not recruiting

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

Primary Systemic AmyloidosisApproved

MacroglobulinemiaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Peritoneum CancerApproved

Approved

Bacterial DiseasePreclinical

Active, not recruiting

Urinary Bladder CarcinomaApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

Adult Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

Primary Systemic AmyloidosisApproved

Approved

MacroglobulinemiaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Showing 10 of 117 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

Trodelvy

37 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04980222

Q4 2026

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT05785754

Phase 2/3Active, not recruiting

Soft Tissue Sarcoma

NCT02180867

Phase 1/2Recruiting

Lenalidomide

NCT04432714

Phase 3Recruiting

Ovarian Cancer

NCT06394492

Phase 3Active, not recruiting

Liver Cancer

NCT03533582

Clinical

Trials by Indication[1]

Breast Cancer39 trials

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03725059·1,240 enrolled

Vaccination of High Risk Breast Cancer Patients

Completed·UUniversity of Arkansas·Phase 1/2·NCT02229084·58 enrolled

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05177796

Show 36 more trials

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005800·45 enrolled

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

Completed·UUniversity of Miami·Phase 2·NCT00499122·41 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03036488·1,174 enrolled

Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191789·65 enrolled

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00455533·384 enrolled

TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen

Withdrawn·JJules Bordet Institute·Phase 2·NCT02053597

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Completed·GGeorge Albert Fisher·Phase 2·NCT00404066·21 enrolled

Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.

Unknown status·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT02506777·96 enrolled

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07441460·1,800 enrolled

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT00365417·45 enrolled

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00021255·3,222 enrolled

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01818063·9 enrolled

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not yet recruiting·CChinese Academy of Medical Sciences·N/A·NCT05287308·500 enrolled

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00944047·32 enrolled

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01275677·3,270 enrolled

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00789581·614 enrolled

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Unknown status·RRussian Academy of Medical Sciences·Phase 2·NCT02685657·164 enrolled

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00102219·77 enrolled

TAC Versus TC for Adjuvant Breast Cancer

Completed·UUS Oncology Research·Phase 3·NCT00493870·1,961 enrolled

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00336791·273 enrolled

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01964391·174 enrolled

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT04081389·9 enrolled

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Completed·—·Phase 2·NCT00546156·104 enrolled

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Completed·—·Phase 2·NCT00146562·135 enrolled

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05113251·927 enrolled

Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Terminated·—·Phase 2·NCT02472353·30 enrolled

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00461344·20 enrolled

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Withdrawn·WWake Forest University Health Sciences·Phase 1·NCT04762901

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Completed·—·Phase 1·NCT00976131·7 enrolled

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Unknown status·AAiping Shi·Phase 2·NCT05088057·30 enrolled

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT01220128·66 enrolled

Lymphoma32 trials

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT06220032·324 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Active, not recruiting·—·Phase 2·NCT03113500·48 enrolled

Show 29 more trials

Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

Completed·UUniversity of Cologne·Phase 1/2·NCT00147875·60 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting· Takeda logo

Takeda·Phase 4·NCT06831370·124 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting·UUniversity of Rochester·Phase 2·NCT03758989·40 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn·FFate Therapeutics·Phase 1·NCT05934097

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Terminated·RRush University Medical Center·Phase 2·NCT02531308·5 enrolled

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02181738·294 enrolled

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Unknown status·SSouthwest Hospital, China·Phase 3·NCT03553537·100 enrolled

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06377566·71 enrolled

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00026208·76 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03033914·82 enrolled

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting·CCStone Pharmaceuticals·Phase 1·NCT05279300·480 enrolled

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04745949·31 enrolled

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Completed·PPolish Lymphoma Research Group·Phase 3·NCT00801281·250 enrolled

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001337·348 enrolled

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Completed· Roche logo

Roche·Phase 3·NCT01332968·1,401 enrolled

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT00512980

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·PPeking University·Phase 3·NCT03952572·244 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04884035·174 enrolled

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06630091·30 enrolled

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01719835·87 enrolled

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00787527·14 enrolled

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00451178·101 enrolled

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1·NCT01060904·51 enrolled

Acute Lymphoblastic Leukemia13 trials

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting·—·Phase 3·NCT03020030·560 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

Show 10 more trials

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01186328·6 enrolled

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02419469·1 enrolled

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Completed·MMassachusetts General Hospital·Phase 1·NCT02228772·19 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT05453500·30 enrolled

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

Diffuse Large B-Cell Lymphoma12 trials

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

Show 9 more trials

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00575406·94 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04980222·46 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated· Roche logo

Roche·Phase 1·NCT04790903·50 enrolled

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT05578976·900 enrolled

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1/2·NCT07124936·97 enrolled

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·PPatrick Reagan·Phase 2·NCT02734771·24 enrolled

Soft Tissue Sarcoma12 trials

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Completed·WWashington University School of Medicine·Phase 2·NCT02584309·73 enrolled

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Completed·UUniversity Health Network, Toronto·Phase 1·NCT03042819·25 enrolled

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Recruiting·OOslo University Hospital·Phase 2·NCT04776525·49 enrolled

Show 9 more trials

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting·PPhilogen S.p.A.·Phase 3·NCT04650984·102 enrolled

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

Completed·VValerio Therapeutics·Phase 1/2·NCT00878800·41 enrolled

Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

Recruiting·SSwiss Cancer Institute·Phase 2·NCT06835049·24 enrolled

A Study of Olaratumab in Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01185964·148 enrolled

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting·FFudan University·Phase 1/2·NCT05774275·52 enrolled

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03283696·24 enrolled

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT02180867·140 enrolled

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

Unknown status·PPhilogen S.p.A.·Phase 2·NCT03420014·114 enrolled

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00102609·41 enrolled

65 more indications

Follicular Lymphoma6 trials

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 4·NCT03817853·114 enrolled

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449252·120 enrolled

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06425302·90 enrolled

Show 3 more trials

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT00715208·55 enrolled

Ovarian Cancer5 trials

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT01358071·119 enrolled

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT03804866·14 enrolled

Show 2 more trials

Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

Unknown status·PPeking University People's Hospital·Phase 1·NCT03542669·9 enrolled

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Active, not recruiting·—·Phase 2·NCT05467670·16 enrolled

Liver Cancer4 trials

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00083226·42 enrolled

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05766605·90 enrolled

Show 1 more trial

Study of Pegylated Human Recombinant Arginase for Liver Cancer

Completed·BBio-Cancer Treatment International Limited·Phase 1·NCT00988195·15 enrolled

Hepatocellular Carcinoma3 trials

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Terminated·TTularik·Phase 2/3·NCT00057382·750 enrolled

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn·AAlbert Koong·Phase 3·NCT01327521

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed·RRehab Werida··NCT05291338·107 enrolled

Gastric Cancer3 trials

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT07486310·30 enrolled

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

Not yet recruiting·OOdense University Hospital·Phase 2·NCT06295094·264 enrolled

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Recruiting·—·Phase 1·NCT04329494·49 enrolled

Leiomyosarcoma3 trials

Lurbinectedin + Doxorubicin In Leiomyosarcoma

Active, not recruiting·MMassachusetts General Hospital·Phase 1/2·NCT05099666·62 enrolled

Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02131480·110 enrolled

A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT04996004·76 enrolled

Multiple Myeloma3 trials

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Completed·UUniversity Hospital Freiburg·Phase 1/2·NCT01394354·34 enrolled

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 3·NCT02362165·236 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Cardiotoxicity2 trials

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not yet recruiting·TTanta University·Phase 1/2·NCT07370506·36 enrolled

The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity

Completed·UUniversity of Miami·Phase 1·NCT00530101·3 enrolled

Neuroblastoma2 trials

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Neoadjuvant Chemotherapy2 trials

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Unknown status·JJilin University·Phase 2·NCT02953184·160 enrolled

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506155·60 enrolled

Doxorubicin2 trials

Pharmacokinetic Study of Doxorubicin in Children With Cancer

Completed·UUniversity Hospital Muenster·Phase 2·NCT01095926·101 enrolled

Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Completed·TTexas Tech University Health Sciences Center·Phase 4·NCT01537029·15 enrolled

Endometrial Cancer2 trials

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Terminated·RR-Pharm·Phase 3·NCT00883116·551 enrolled

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07044336·700 enrolled

Mantle Cell Lymphoma2 trials

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00878254·25 enrolled

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

T-cell acute lymphoblastic leukemia2 trials

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03384654·47 enrolled

Lenalidomide1 trial

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04432714·81 enrolled

Solid Tumours1 trial

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Recruiting·RRace Oncology Ltd·Phase 1·NCT06815575·53 enrolled

Lung Cancer1 trial

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Completed·PPharmaMar·Phase 3·NCT02566993·613 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Terminated·MMeyer Children's Hospital IRCCS·Phase 2·NCT02758366·21 enrolled

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00796120·121 enrolled

Chemotherapy1 trial

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

Pancreatic Cancer1 trial

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Terminated·HHelix BioPharma Corporation·Phase 1/2·NCT04203641·28 enrolled

Childhood Acute Lymphoblastic Leukemia1 trial

Treatment of Childhood Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00165087·491 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Unknown status·CCzech Lymphoma Study Group·Phase 2·NCT05006664·33 enrolled

Clinical Trial1 trial

Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT02958163·3 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Urinary Tract Cancer1 trial

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02412670·36 enrolled

DLBCL1 trial

Split-Dose R-CHOP for Older Adults With DLBCL

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT03943901·27 enrolled

Maximum Tolerated Dose1 trial

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00288431·37 enrolled

Lymphoproliferative Disorder1 trial

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Recruiting·JJennifer Amengual·Phase 2·NCT06954805·30 enrolled

Adenocarcinoma1 trial

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Completed·—·Phase 2·NCT00165191·32 enrolled

Chidamide1 trial

Chidamide Plus R-CHOP in Elderly DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT02753647·49 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Unresectable Solid Tumor1 trial

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Completed·PPharmaMar·Phase 1·NCT01970540·122 enrolled

Prostate Cancer1 trial

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02494713·4 enrolled

Pediatric Brain Tumor1 trial

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

Terminated·WWashington University School of Medicine·Phase 2·NCT02372409·6 enrolled

B-cell non-Hodgkins lymphoma1 trial

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Completed·—·Phase 2·NCT00577629·39 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Completed·RRuijin Hospital·Phase 4·NCT01358253·100 enrolled

Necrosis1 trial

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Completed·MMara Chambers·Phase 2·NCT01205503·32 enrolled

Advanced Sarcoma1 trial

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting·IInstitut Bergonié·Phase 2·NCT04874311·80 enrolled

Advanced Solid Tumors1 trial

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00722293·111 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Monotherapy1 trial

Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

Unknown status·SShi-Ming Lin·Phase 2·NCT01858207·60 enrolled

Bladder Cancer1 trial

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT02177695·237 enrolled

Hypofractionated Radiotherapy1 trial

Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

Unknown status·—·Phase 2·NCT02812654·70 enrolled

Pediatric Patients1 trial

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Terminated·MMayo Clinic·Phase 1·NCT04213794·2 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Wilms tumor1 trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Recruiting·CChildren's Oncology Group·Phase 3·NCT06401330·1,656 enrolled

Efficacy1 trial

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209222·360 enrolled

Solid Tumors1 trial

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Recruiting·GGeorgetown University·Phase 1·NCT05661201·24 enrolled

Histiocytosis1 trial

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Unknown status·—·Phase 3·NCT02631109·120 enrolled

Solid Tumor1 trial

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1/2·NCT04008797·301 enrolled

Adult ALL1 trial

ALL Adult Consortium Trial: Adult ALL Trial

Completed·—·Phase 2·NCT00476190·112 enrolled

Adrenocortical Carcinoma1 trial

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Completed·CCollaborative Group for Adrenocortical Carcinoma Treatment·Phase 3·NCT00094497·304 enrolled

Uterine Leiomyosarcoma1 trial

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting·UUNICANCER·Phase 2·NCT06524583·198 enrolled

Renal Cell Carcinoma1 trial

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00068393·39 enrolled

Cervical Cancer1 trial

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03340376·48 enrolled

Cytoreductive Surgery1 trial

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Completed·HHoly Name Medical Center, Inc.··NCT03604653·10 enrolled

Advanced or Metastatic Solid Tumors1 trial

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting·DDynamiCure Biotechnology·Phase 1·NCT05785754·320 enrolled

Urothelial Carcinoma1 trial

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Completed·—·Phase 2·NCT00808639·39 enrolled

Advanced Cancer1 trial

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02377752·25 enrolled

Advanced Cancers1 trial

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00798252·111 enrolled

Hematologic Malignancies1 trial

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02419755·12 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DOXORUBICIN HYDROCHLORIDE

NDA NDA050467

Dec 23, 1987

DOXORUBICIN HYDROCHLORIDE

NDA NDA050629

Nov 17, 1995

DOXIL (LIPOSOMAL)

NDA NDA050718

Sources

References

[1]
ClinicalTrials.gov — 671 trial records for Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Adriamycin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050718). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Alpha Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Adriamycin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Breast Cancer39 trials

Lymphoma32 trials

Acute Lymphoblastic Leukemia13 trials

Diffuse Large B-Cell Lymphoma12 trials

Soft Tissue Sarcoma12 trials

Follicular Lymphoma6 trials

Ovarian Cancer5 trials

Liver Cancer4 trials

Hepatocellular Carcinoma3 trials

Gastric Cancer3 trials

Leiomyosarcoma3 trials

Multiple Myeloma3 trials

Cardiotoxicity2 trials

Neuroblastoma2 trials

Neoadjuvant Chemotherapy2 trials

Doxorubicin2 trials

Endometrial Cancer2 trials

Mantle Cell Lymphoma2 trials

T-cell acute lymphoblastic leukemia2 trials

Lenalidomide1 trial

Solid Tumours1 trial

Lung Cancer1 trial

Real-world Study1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Endometrial Carcinoma1 trial

Pediatric ALL1 trial

Efficacy and Safety1 trial

Chemotherapy1 trial

Pancreatic Cancer1 trial

Childhood Acute Lymphoblastic Leukemia1 trial

Brentuximab Vedotin1 trial

Clinical Trial1 trial

Induction Chemotherapy1 trial

Urinary Tract Cancer1 trial

DLBCL1 trial

Maximum Tolerated Dose1 trial

Lymphoproliferative Disorder1 trial

Adenocarcinoma1 trial

Chidamide1 trial

Ewing's Sarcoma1 trial

Unresectable Solid Tumor1 trial

Prostate Cancer1 trial

Pediatric Brain Tumor1 trial

B-cell non-Hodgkins lymphoma1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Necrosis1 trial

Advanced Sarcoma1 trial

Advanced Solid Tumors1 trial

Trial1 trial

Monotherapy1 trial

Bladder Cancer1 trial

Hypofractionated Radiotherapy1 trial

Pediatric Patients1 trial

Advanced Stage1 trial

Wilms tumor1 trial

Efficacy1 trial

Solid Tumors1 trial

Histiocytosis1 trial

Solid Tumor1 trial

Adult ALL1 trial

Adrenocortical Carcinoma1 trial

Uterine Leiomyosarcoma1 trial

Renal Cell Carcinoma1 trial

Cervical Cancer1 trial

Cytoreductive Surgery1 trial

Advanced or Metastatic Solid Tumors1 trial

Urothelial Carcinoma1 trial

Advanced Cancer1 trial

Advanced Cancers1 trial

Hematologic Malignancies1 trial

FDA Approval Timeline[5]

References

Drug Info